EMA APPROVAL OF DRUGS ON THE BASIS OF PIVOTAL NON-COMPARATIVE PHASE II TRIAL DATA

被引：0
|
作者：
Macaulay, R. [1 ]
机构：
[1] HERON Hlth, London, England
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.009
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A324 / A324
页数：1
相关论文
共 50 条
  • [1] Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: A non-comparative randomized phase II trial
    Ducreux, Michel
    Giovannini, Marc
    Baey, Charlotte
    Llacer, Carmen
    Bennouna, Jaafar
    Adenis, Antoine
    Peiffert, Didier
    Mornex, Francoise
    Abbas, Moncef
    Boige, ValSrie
    Pignon, Jean-Pierre
    Conroy, Thierry
    Cellier, Patrice
    Juzyna, Beata
    Viret, Frederic
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) : 950 - 955
  • [2] Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial
    Kok, M.
    Horlings, H. M.
    van de Vijver, K.
    Wiersma, T.
    Russell, N.
    Voorwerk, L.
    Sikorska, K.
    van Werkhoven, E.
    Mandjes, I. A.
    Kemper, I.
    Foekema, J.
    Wilgenhof, S.
    Chalabi, M.
    Stouthard, J.
    Sonke, G. S.
    Cullen, D.
    Salgado, R.
    Schumacher, T. N. M.
    Blank, C. U.
    Linn, S. C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM)
    Hegazy, Mohamad
    Wahba, Hanan
    NEUROLOGY, 2012, 78
  • [4] ECONOMIC EVALUATION OF THERAPIES SUBMITTED WITH NON-COMPARATIVE SINGLE ARM PHASE II DATA: A COMPARISON OF NICE AND HAS EFFICIENCY OPINIONS
    Tchouen, N.
    Gaudin, A. F.
    Baklouti, M.
    VALUE IN HEALTH, 2022, 25 (12) : S65 - S65
  • [5] EVIDENCE FOR A LOWERED THRESHOLD FOR FDA APPROVAL OF ONCOLOGICS BASED ON SINGLE-ARM PHASE II DATA, COMPARED TO THE EMA
    Macaulay, R.
    VALUE IN HEALTH, 2014, 17 (03) : A98 - A98
  • [6] Preliminary Results from a Multicenter, Phase II, Randomized, Non-comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma
    Alexander, B. M.
    Quant, E. C.
    Batchelor, T. B.
    Schiff, D. S.
    Kaley, T. J.
    Drappatz, J.
    Wong, E. T.
    Mikkelsen, T.
    Weiss, S. E.
    Wen, P. Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S180 - S180
  • [7] A phase II, open-label, non-comparative study of Botulinum toxin in Restless Legs Syndrome
    Ghorayeb, Imad
    Benard, Antoine
    Vivot, Alexandre
    Tison, Francois
    Burbaud, Pierre
    SLEEP MEDICINE, 2012, 13 (10) : 1313 - 1316
  • [8] Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
    N C Tebbutt
    M M Cummins
    T Sourjina
    A Strickland
    G Van Hazel
    V Ganju
    D Gibbs
    M Stockler
    V Gebski
    J Zalcberg
    British Journal of Cancer, 2010, 102 : 475 - 481
  • [9] RANDOMIZED, NON-COMPARATIVE, PHASE II TRIAL OF BEVACIZUMAB AND TRABECTEDIN WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER (ROC) WOMEN
    Colombo, N.
    Nicoletto, M. O.
    Lissoni, A.
    Scambia, G.
    Tognon, G.
    Negri, E.
    Galli, F.
    Biagioli, E.
    Rulli, E.
    Fossati, R.
    D'Incalci, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 277 - 277
  • [10] Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
    Tebbutt, N. C.
    Cummins, M. M.
    Sourjina, T.
    Strickland, A.
    Van Hazel, G.
    Ganju, V.
    Gibbs, D.
    Stockler, M.
    Gebski, V.
    Zalcberg, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 475 - 481
12345